DUBLIN--(BUSINESS WIRE)--The "Parkinson's Disease Treatment - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
The Global Parkinson's Disease Treatment Market accounted for $4.08 billion in 2017 and is expected to reach $7.93 billion by 2026 growing at a CAGR of 7.7%.
Growing geriatric population coupled with neurological disorders, increasing investments in research & development activities, and raising healthcare awareness are some of the factors propelling the market growth during the forecast period. However, availability of other treatments is hindering the market growth.
By therapeutic class, Carbidopa/Levodopa segment is prognosticated to witness strong growth rate over the forecast period due to its potentiality and large acceptance for the parkinson's disease treatment. Besides, online pharmacies are projected to grow at a higher growth rate during the forecast period.
By region, Asia Pacific is expected to witness highest growth rate due to growing medical tourism trend and raising medical infrastructure. Europe is dominating the global market with highest market revenue during the forecast period. This dominance is driven by increasing geriatric population and raising expenses on healthcare.
- GlaxoSmithKline PLC
- Boehringer Ingelheim
- Daiichi Sankyo
- Impax Laboratories Inc.
- Salix Pharmaceuticals
- Sun Pharma
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals
- Wockhardt Limited
For more information about this report visit https://www.researchandmarkets.com/research/sh3n2w/2018_global?w=4